Voya Investment Management LLC Alaunos Therapeutics, Inc. Transaction History

Voya Investment Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $32,018 - $96,837	-78,095 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $10,394 - $18,023	-9,536 Reduced 10.88%	78,095 $85,000
Q2 2021 Aug 16, 2021	SELL	$2.63 - $3.67 $20,824 - $29,059	-7,918 Reduced 8.29%	87,631 $231,000
Q1 2021 May 17, 2021	BUY	$2.82 - $5.6 $8,826 - $17,528	3,130 Added 3.39%	95,549 $344,000
Q4 2020 Feb 16, 2021	BUY	$2.09 - $3.09 $37,143 - $54,915	17,772 Added 23.81%	92,419 $233,000
Q2 2020 Aug 14, 2020	SELL	$2.2 - $3.71 $33,508 - $56,507	-15,231 Reduced 16.95%	74,647 $245,000
Q1 2020 May 15, 2020	BUY	$1.9 - $4.98 $23,434 - $61,423	12,334 Added 15.91%	89,878 $220,000
Q4 2019 Feb 14, 2020	BUY	$3.95 - $5.35 $58,594 - $79,361	14,834 Added 23.65%	77,544 $366,000
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $28,214 - $43,951	7,089 Added 12.75%	62,710 $366,000
Q2 2018 Aug 14, 2018	SELL	$3.02 - $4.94 $15,586 - $25,495	-5,161 Reduced 8.49%	55,621 $168,000
Q3 2017 Nov 14, 2017	BUY	$4.99 - $6.57 $303,302 - $399,337	60,782	60,782 $373,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Voya Investment Management LLC with notifications on news.